Navigation Links
Amarin Secures Global Intellectual Property Rights for Lipid Programs

LONDON, March 3 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has signed an exclusive license with Scarista Limited ("Scarista") for the development and commercialization rights to a broad intellectual property portfolio in the field of lipid science. This intellectual property portfolio is complementary to Amarin's existing lipid-based development programs including AMR101 and its targeted lipid transport technology. The transaction consideration comprises an upfront fee to Scarista of $0.5 million and royalties upon commercialization.

In 2004, Amarin licensed rights to this portfolio, covering applications in diseases of the central nervous system for North America, the EU and Japan. This new license provides Amarin with rights to all remaining therapeutic areas and all territories worldwide.

Thomas Lynch, Amarin's Chairman and Chief Executive Officer, commented "This is an important strategic step for Amarin that strengthens our position to establish global partnerships with our lipid programs. In addition, access to broader potential applications will allow us to take advantage of new opportunities outside the CNS field, such as cardiovascular disease."

Declan Doogan M.D., Amarin's Head of Research and Development, added "The field of lipid science has matured significantly in the past two decades, and now contributes a range of important prescription drug treatments for various medical conditions associated with the vascular system, including cardiovascular disease. In addition, real medical benefits have been identified with new development stage candidates based on lipid science, achieving recognition in prestigious scientific publications. Amarin enjoys a prominent place as a sponsor of such research and development to bring much needed treatments to important medical conditions."

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.

Disclosure Notice

The information contained in this document is as of March 3, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks relating to the Company's ability to maintain its Nasdaq listing; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International and US generally accepted accounting principles; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the SEC on March 5, 2007, Amarin's statutory annual report for the year ended 31 December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007, Amarin's Report of Foreign Issuer (Updated and Additional Risk Factors) furnished on a Form 6-K to the SEC on January 8, 2008 and in Amarin's other Reports of Foreign Issuer on Form 6-K furnished to the SEC.

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amarin Appoints Dr. William Mason as Lead Independent Director
2. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
3. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
4. Amarin Signs Agreement to Acquire Ester Neurosciences
5. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
6. Amarin Announces Initiation of Cardiovascular Development Strategy
7. Amarin to Present at 4th Annual Bio Investor Forum
8. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
9. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
10. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
11. Taligen Therapeutics Secures Series B Financing
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International ... and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. ... 2015, where ISPE hosted the largest number of attendees in more than a ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by ... known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , ... have embraced this type of racing and several new model aviation pilots have joined ...
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Twist ... announced that Emily Leproust, Ph.D., Twist Bioscience chief ... Jaffray Healthcare Conference on December 1, 2015 at ... Hotel in New York City. --> ... . Twist Bioscience is on Twitter. ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015  As new scientific discoveries deepen our ... other healthcare providers face challenges in better using that ... In addition, as more children continue to survive pediatric ... and old age. John M. Maris, M.D ... of Philadelphia (CHOP) . --> John ...
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
Breaking Biology News(10 mins):